Theranostic nanoparticles: Chen and colleagues provide an overview of the current and prospective status of these multifunctional nanosystems, including challenges in highly specific targeting of tumors.
Page 1919
Customer satisfaction: Hicks offers perspective on results of surveys that seek the opinion of referring clinicians about oncologic 18F-FDG PET/CT reporting and previews an article on this topic in this issue of JNM.
Page 1923
Perception of PET/CT misinterpretation: Karantanis and colleagues detail results of a study designed to collect pertinent information from physicians referring patients for oncologic 18F-FDG PET/CT, with surprising findings about clinicians’ most frequent complaint.
Page 1925
DWI in whole-body PET/MR: Grueneisen and colleagues assess the diagnostic benefit of diffusion-weighted imaging in an 18F-FDG PET/MR protocol for whole-body staging of women with primary or recurrent malignancies of the pelvis.
Page 1930
International use of PET in DLBCL: Carr and colleagues report on a multinational study of PET for risk stratification in diffuse large B-cell lymphoma and ask whether biologic and health care system diversity influence response as assessed by interim PET.
Page 1936
99mTc-folate M2 macrophage plaque imaging: Jager and colleagues explore the presence of activated macrophages in human atherosclerotic plaques with 99mTc-folate imaging and evaluate whether this technique can discriminate between M1- and M2-like macrophage phenotypes.
Page 1945
MBF methods for 82Rb: Murthy and colleagues compare differences among multiple methods and models for quantification of myocardial blood flow and myocardial flow reserve using 82Rb PET and assess their impact on prognostic assessment in a large clinical dataset.
Page 1952
PET and SPECT in dementia: O’Brien and colleagues investigate the comparative diagnostic accuracy of 18F-FDG PET and HMPAO SPECT in individuals with Alzheimer disease or dementia with Lewy bodies.
Page 1959
123I-CLINDE SPECT: Feng and colleagues provide a method for and documentation of quantification of translocator protein binding using SPECT and a promising ligand in patients with cerebral stroke or glioblastoma multiforme.
Page 1966
18F-mefway characterization: Hillmer and colleagues examine in humans the in vivo cerebral binding profile and metabolism of this serotonin-1A receptor that is implicated in an array of neurologic and psychiatric disorders.
Page 1973
Scintigraphic imaging of endocarditis: Rouzet and colleagues compare the respective performances of 18F-FDG PET and leukocyte scintigraphy for diagnosis of prosthetic valve endocarditis in 39 patients.
Page 1980
FACBC physiologic uptake: Schuster and colleagues explore common physiologic uptake patterns, as well as incidental findings and variants, in patients who have undergone PET imaging with this synthetic amino acid analog.
Page 1986
11C-CURB dosimetry: Boileau and colleagues investigate in humans the whole-body biodistribution and radiation dosimetry of this novel 11C-labeled suicide irreversible tracer developed as a surrogate measure of activity of the fatty acid amide hydrolase.
Page 1993
Dose reduction using SUV: Cheng and colleagues explore how the injected 18F-FDG dose can be lowered while maintaining validity in comparing standardized uptake values between studies.
Page 1998
Multimodality imaging of dementia: Nazrallah and Wolk provide an educational overview of imaging in neurodegenerative dementia, including a focus on the potential for hybrid PET/MR imaging to improve diagnosis and management.
Page 2003
Specific activity of antibody cocktails: Pasternack and colleagues look at ways in which combinations of radiolabeled antibodies can be formulated to overcome the limitations of nonuniform dose distributions among disseminated tumor cells in targeted α therapy.
Page 2012
188Re-P2045 and tumor growth: Nelson and colleagues describe studies designed to determine whether this radiolabeled peptide analog of somatostatin can inhibit pancreatic tumor xenograft growth in a mouse model.
Page 2020
Imaging DNA damage in breast cancer: Cornelissen and colleagues investigate whether 111In-anti-γH2AX-TAT is able to detect the DNA damage response during mammary oncogenesis in mice.
Page 2026
89Zr-labeled immuno-PET and HCC: Sham and colleagues assess the potential of 89Zr-conjugated F(ab′)2 fragments directed against glypican-3 as a diagnostic immuno-PET probe in hepatocellular carcinoma.
Page 2032
18F-FDG uptake in CRC with mutated KRAS: Iwamoto and colleagues explore through in vivo and small-animal studies the mechanisms by which KRAS gene mutations, which occur in ∼40% of colorectal cancers, increase 18F-FDG accumulation.
Page 2038
Immuno-PET targeting of STEAP1: Doran and colleagues describe preparation and evaluation of 89Zr-2109A, a radiotracer for PET derived from a fully humanized monoclonal antibody to cell surface protein 6 transmembrane epithelial antigen of prostate 1 in preclinical prostate cancer models.
Page 2045
GRPR antagonists for prostate cancer PET: Chatalic and colleagues compare 3 novel gastrin-releasing peptide receptor–targeted radiolabeled tracers for PET imaging of prostate cancer.
Page 2050
99mTc-peptide melanoma imaging: Guo and Miao examine the effects of amino acid, hydrocarbon, and polyethylene glycol linkers on the melanoma targeting and imaging properties of several novel 99mTc-labeled peptides.
Page 2057
Myocardial perfusion IQ SPECT: Caobelli and colleagues establish the lower limit of radioactivity that can be administered to patients for myocardial perfusion IQ SPECT and the minimum acquisition time that will preserve diagnostic accuracy.
Page 2064
PET AC from MR: Roy and colleagues detail a PET attenuation correction method using a patch-matching approach to synthesize CT images from ultrashort echo-time MR images, with resulting improvements in PET reconstruction accuracy.
Page 2071
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.